Intetumumab

Intetumumab is a human monoclonal antibody targeting integrins^[1] that was being studied for the treatment of solid tumors.^[2]

Intetumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	integrin alpha-V
Clinical data
ATC code	none
Identifiers
CAS Number	725735-28-4 N
ChemSpider	none
UNII	GQE1BJE2NI
KEGG	D09631
Chemical and physical data
Formula	C6468H10008N1744O2006S40
Molar mass	145579.81 g·mol−1
NY (what is this?)  (verify)

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.^[3]